{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:11:04Z","timestamp":1790727064455,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016827","name":"Deciphera Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003107","name":"Bundesministerium f\u00fcr Gesundheit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.esmoop.2022.100520","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T19:56:50Z","timestamp":1656014210000},"page":"100520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma"],"prefix":"10.1016","volume":"7","author":[{"given":"F.","family":"Janku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Shoumariyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Psoinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ruiz-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.esmoop.2022.100520_bib1","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1242\/dev.127.24.5379","article-title":"Signaling and transcriptional regulation in the neural crest-derived melanocyte lineage: interactions between KIT and MITF","volume":"127","author":"Hou","year":"2000","journal-title":"Development"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100520_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1034\/j.1600-0749.2003.00055.x","article-title":"The role of Kit-ligand in melanocyte development and epidermal homeostasis","volume":"16","author":"Wehrle-Haller","year":"2003","journal-title":"Pigment Cell Res"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100520_bib3","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/sj.jid.5700125","article-title":"Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes","volume":"126","author":"Alexeev","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"issue":"26","key":"10.1016\/j.esmoop.2022.100520_bib4","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2022.100520_bib5","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100520_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jid.2017.07.839","article-title":"STAT3 mediates nilotinib response in KIT-Altered melanoma: a phase II multicenter trial of the French Skin Cancer Network","volume":"138","author":"Delyon","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100520_bib7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/bjc.2014.287","article-title":"Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma","volume":"111","author":"Carlino","year":"2014","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100520_bib8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1755-148X.2010.00671.x","article-title":"Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure","volume":"23","author":"Handolias","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"issue":"21","key":"10.1016\/j.esmoop.2022.100520_bib9","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT gene mutations and copy number in melanoma subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100520_bib10","series-title":"Prescribing Information","year":"2020"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100520_bib11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"9440","key":"10.1016\/j.esmoop.2022.100520_bib12","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100520_bib13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100520_bib14","series-title":"Prescribing Information","year":"2021"},{"issue":"26","key":"10.1016\/j.esmoop.2022.100520_bib15","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100520_bib16","series-title":"Prescribing Information","year":"2021"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100520_bib17","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100520_bib18","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100520_bib19","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ejca.2006.01.030","article-title":"KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours","volume":"42","author":"Debiec-Rychter","year":"2006","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100520_bib20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/modpathol.2008.2","article-title":"Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases","volume":"21","author":"Lasota","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.esmoop.2022.100520_bib21","doi-asserted-by":"crossref","first-page":"22886","DOI":"10.18632\/oncotarget.25094","article-title":"Analysis of KIT gene mutations in patients with melanoma of the head and neck mucosa: a retrospective clinical report","volume":"9","author":"Bezerra Toscano de Mendon\u00e7a","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100520_bib22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jid.2017.09.003","article-title":"JAK-ing up the response to KIT inhibition","volume":"138","author":"Yang","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100520_bib23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jid.2018.10.009","article-title":"Tyrosine kinase inhibitor and immune checkpoint inhibitor responses in KIT-mutant metastatic melanoma","volume":"139","author":"McKean","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.esmoop.2022.100520_bib24","unstructured":"National Comprehensive Cancer Network Guidelines. Melanoma: Cutaneous (version 2.2021).\u00a02021."},{"issue":"28","key":"10.1016\/j.esmoop.2022.100520_bib25","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1200\/JCO.20.00522","article-title":"Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase I study of ripretinib","volume":"38","author":"Janku","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100520_bib26","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/1078-0432.CCR-11-1987","article-title":"Sunitinib therapy for melanoma patients with KIT mutations","volume":"18","author":"Minor","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100520_bib27","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1101\/gad.329771.119","article-title":"Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities","volume":"33","author":"Rambow","year":"2019","journal-title":"Genes Dev"},{"issue":"7658","key":"10.1016\/j.esmoop.2022.100520_bib28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature22794","article-title":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","volume":"546","author":"Shaffer","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100520_bib29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100520_bib30","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/annonc\/mdx079","article-title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","volume":"28","author":"Guo","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100520_bib31","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1634\/theoncologist.2014-0468","article-title":"Clinical activity of ipilimumab in acral melanoma: a retrospective review","volume":"20","author":"Johnson","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2022.100520_bib32","doi-asserted-by":"crossref","unstructured":"Bauer S, Heinrich MC, George S, et\u00a0al. Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogenous KIT\/PDGFRA mutations in the phase 3 INVICTUS study. Clin Cancer Res. 2021;27(23):6333-6342.","DOI":"10.1158\/1078-0432.CCR-21-1864"},{"key":"10.1016\/j.esmoop.2022.100520_bib33","first-page":"1","article-title":"Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor: an analysis of the INVICTUS study","volume":"25","author":"Zalcberg","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2022.100520_bib34","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2021.07.010","article-title":"Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour","volume":"155","author":"George","year":"2021","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100520_bib35","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1634\/theoncologist.2015-0161","article-title":"Phase II trial of nilotinib in patients with metastatic malignant melanoma harboring KIT gene aberration: a multicenter trial of Korean cancer study group (UN10-06)","volume":"20","author":"Lee","year":"2015","journal-title":"Oncologist"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:22Z","timestamp":1761856162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922001417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2059702922001417"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100520","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100520"}}